When was Intarcia founded?

Intarcia was founded in 1995 and became a unicorn in 2014, reaching the milestone in 19 years. It raised its 1st funding round 5 years after its incorporation.

Where is Intarcia located?

Intarcia is headquartered in Boston, United States. It is registered at Boston, Massachusetts.

How many employees does Intarcia have?

As of Sep 30, 2026, the latest employee count at Intarcia is 68.

Is Intarcia a funded company?

Intarcia is a funded company, having raised a total of $1.89B across 22 funding rounds to date. The company's 1st funding round was a $38M Series C round, raised on Sep 25, 2000.

How much is Intarcia worth?

The latest valuation of Intarcia is $3.5B as of Dec 28, 2020.

When was the latest funding round of Intarcia?

Intarcia's latest funding was a $198M Series J round on Jan 14, 2020, with participation from 0 investor.

Is Intarcia a Drug Delivery company?

The primary sectors of Intarcia are Drug Delivery and Diabetes.

Where does Intarcia rank among its competitors?

Intarcia ranks 56th amongst 290 active competitors, of which 103 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Intarcia?

Intarcia's top competitors include Sana Biotechnology, Adocia and Kailera. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Intarcia - 2026 Company Profile, Funding & Competitors

Sectors and market segments that Intarcia operate in

Intarcia serves in the Life Sciences market segments.The primary business model of Intarcia are:

Company Details

Intarcia Therapeutics offers a drug delivery platform technology. The product is a subcutaneous osmotic mini-pump containing the necessary volume of the drug. Once implanted under the skin, water from the extracellular fluid enters the device and osmotic pressure drives a piston which delivers the drug.

Website: intarcia.com
Social
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

1995

Location

Boston, United States

Stage

Series J

Total Funding

$1.89B in 22 rounds

Latest Funding Round

Series J, Jan 14, 2020, $198M

Post Money Valuation

$3.5B as on Dec 28, 2020

Investors

New Leaf Venture Partners & 43 more

Ranked

56^th among 290 active competitors

Employee Count

68 as on Sep 30, 2026

Similar Companies

Sana Biotechnology & 357 more

View Intarcia's full profile

Intarcia is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Intarcia Therapeutics, Inc. CIN: 680364181 , United States, Active	Dec 31, 1999	-	335 (As on Dec 31, 2019)	-

Intarcia has raised a total funding of $1.89B over 22 rounds. Its first funding round was on Sep 25, 2000. Intarcia has 44 institutional investors.

Here is the list of recent funding rounds of Intarcia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 14, 2020	$198M	Series J	-	-	-	-
Jan 17, 2018	$8M	Series J	-	-	Ascent Venture Partners	Osage Partners, NXT Ventures
Aug 03, 2017	$525M	Series J	-	-	Gates	-

Access funding benchmarks and valuations. Sign up today!

View details of Intarcia's funding rounds and investors

Intarcia's employee count trend

Intarcia has 68 employees as of Sep 26. Here is Intarcia's employee count trend over the years:

Uncover Intarcia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Intarcia include Sana Biotechnology, Adocia and Kailera. Here is the list of Top 10 competitors of Intarcia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
2nd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
3rd	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	65/100
4th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Deep Track Capital & 17 others	65/100
5th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, Humboldt Fund & 7 others	65/100
6th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
7th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	64/100
8th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
9th	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Patient Square Capital, Foresite Capital ... & 16 others	64/100
10th	Veralox Therapeutics 2017, Frederick (United States), Series B	Developer of small molecules for treating thrombosis and diabetes pathologies	$47.5M	Sanofi Ventures, T1D Fund & 13 others	62/100
56th	Intarcia 1995, Boston (United States), Series J	Provider of osmotic pump for subcutaneous drug delivery	$1.89B	Adams Street Partners, Brentwood Associates ... & 42 others	47/100